We chatted to IronRidge Resources' CEO Vincent Mascolo who explains why the company has become a lithium explorer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,306.00
Bid: 2,306.00
Ask: 2,308.00
Change: -33.00 (-1.41%)
Spread: 2.00 (0.09%)
Open: 2,325.00
High: 2,393.00
Low: 2,306.00
Yest. Close: 2,339.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Hikma Pharma says US FDA lifts warning on Eatontown facility

April 2 (Reuters) - Hikma Pharmaceuticals Plc said on Wednesday that the U.S. Food and Drug Administration had lifted the warning on its Eatontown facility in New Jersey where it makes oral products for the U.S. market. The Jordanian company, which makes and markets branded and non-branded

2 Apr 14 06:49

DIRECTOR DEALINGS: Hikma Pharma Executives Receive Share Awards

LONDON (Alliance News) - Hikma Pharmaceuticals PLC said Monday that a group of executives, including Chief Financial Officer Khalid Nabilsi, had received share awards that had vested.<br /><br />The shares were acquired as follows:<br /><br /> <table class="bp" style="width: 495px; height:

24 Mar 14 12:07

MARKET COMMENT: FTSE 100 Snaps A Three-Week Losing Streak

LONDON (Alliance News) - The FTSE 100 closed fractionally higher Friday, ensuring that it ended the week in the black for the first time in four weeks despite losses mid-week due to the UK budget and a press conference by Federal Reserve Chair Janet Yellen. There was little in the way of ma

21 Mar 14 17:42

FTSE 250 movers: Crest Nicholson hit by reports of major shareholder sale

Crest Nicholson dropped after Bloomberg reported that the housebuilder's largest publicly disclosed shareholder, Deutsche Bank, is disposing of as many as 16.5m shares. The German bank is thought to have a 10 per cent stake in the company. Pharmaceuticals firm Hikma was also trading in the red toda

21 Mar 14 14:00

Jefferies downgrades Hikma on limited upside

Jefferies has lowered its recommendation for Hikma Pharmaceuticals from 'buy' to 'hold' and slashed its target price from 1,500p to 1,250p, saying that upside for the stock is now limited after its recent strong run. "We continue to view Hikma as a quality business but re-evaluate the stock after a

21 Mar 14 12:14

UK WINNERS & LOSERS: Bookmakers Continue To Fall

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Friday. ------- FTSE 100 - WINNERS Meggitt, up 1.2%. UBS has upgraded the engineering company to Buy, from Neutral, and increased its price target to 530.00 pen

21 Mar 14 12:00

London midday: Stocks set for weekly gain as miners rise

- Miners recover after recent slump - Obama imposes more sanctions on Russia - Markets await speeches from Fed officials - Burberry, RBS, Hikma hit by broker downgrades techMARK 2,807.91 +0.27% FTSE 100 6,564.71 +0.34% FTSE 250 16,228.56 +0.07% UK equities were trading higher on Friday with the FT

21 Mar 14 11:45

MARKET COMMENT: UK Stocks Mixed As Investors Starved Of Fresh Data

LONDON (Alliance News) - UK stocks are narrowly mixed Friday, shrugging off strong gains posted by Asian and US equities overnight, amid a dearth of fresh UK macroeconomic data. By mid-morning, the FTSE 100 is up 0.4% at 6,565.69, while the FTSE 250 is down 0.1% at 16,207.53, and the AIM Al

21 Mar 14 10:56

UK BROKER RATINGS: Nomura Cuts View On Mining Sector

LONDON (Alliance News) - The following UK shares received analyst recommendations Friday morning:<br />----------<br /><strong>FTSE 100</strong><br />----------<br />UBS RAISES MEGGITT TO 'BUY' ('NEUTRAL') - TARGET 520 (530) PENCE <br />----------<br />BARCLAYS CUTS RBS TO 'EQUAL WEIGHT' ('OVE

21 Mar 14 10:08

Friday broker round-up UPDATE

Anglo American: Nomura reduces target price from 1550p to 1475p and retains a neutral rating. Antofagasta: Nomura cuts target price from 800p to 720p and stays with its reduce rating. Canaccord Genuity reduces target price from 1030p to 880p, while its buy recommendation is kept. ASOS: UBS reduces

21 Mar 14 09:36

London open: Mining stocks provide a lift early on

- Miners recover after recent slump - Obama imposes more sanctions on Russia - Markets await speeches from Fed officials techMARK 2,803.23 +0.11% FTSE 100 6,565.89 +0.36% FTSE 250 16,219.13 +0.01% UK equities opened slightly higher on Friday as decent gains in the mining sector lifted the resource

21 Mar 14 08:27

Tuesday broker round-up UPDATE

Antofagasta: Investec places its target price (prev.: 753p) under review, while leaving its sell recommendation unchanged. Ashtead Group: Credit Suisse raises target price from 1000p to 1100p and stays with its outperform rating. UBS increases target price from 875p to 1020p retaining its buy recom

18 Mar 14 08:58

UK BROKER RATINGS: Merill Lynch Cuts Tesco To Underperform

LONDON (Alliance News) - The following UK shares received analyst recommendations Monday morning:<br />----------<br /><strong>FTSE 100</strong><br />----------<br />BERENBERG CUTS SSE PRICE TARGET TO 1320 (1570) PENCE - 'HOLD' <br />----------<br />BERENBERG CUTS REED ELSEVIER TO 'HOLD' ('BUY

17 Mar 14 10:07

Monday broker round-up UPDATE

Admiral Group: Credit Suisse raises target price from 1340p to 1425p and keeps a neutral rating. African Barrick Gold: Canaccord Genuity ups target price from 315p to 330p and maintains a buy recommendation. Amara Mining: Canaccord Genuity moves target price from 25p to 33p and reiterates its buy

17 Mar 14 08:31

Thursday tips round-up: Ocado, Hikma Pharmaceuticals

Ocado's share price is riding on a lot of assumptions. So much so that in a rational market its shares should not be where they are and they should not be headed any higher. At the moment it is trading at a price-to-earnings multiple of 200 and even if it meets forecasts that would still leave share

13 Mar 14 10:09

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.